Nebivolol Accord-Uk (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Accord-Uk, is a beta blocker presented as an oral tablet for oral administration. It selectively blocks β1‑adrenergic receptors and promotes nitric‑oxide‑mediated vasodilation, helping to lower elevated blood pressure and to improve cardiac function in patients with chronic heart failure. The product conforms to EU regulatory standards.

GNH USA supplies Nebivolol Accord-Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and compliance with local import regulations.

Nebivolol, a selective β1‑adrenergic blocker with nitric‑oxide‑mediated vasodilation, is employed in the management of cardiovascular disorders where lowering blood pressure or supporting cardiac output is required, particularly in adult patients.

- Hypertension: Reduces systolic and diastolic blood pressure, improving overall vascular control in adults with primary hypertension. - Heart failure: Enhances left ventricular ejection fraction and reduces hospitalization risk in patients with chronic heart failure with reduced ejection fraction. - Cardiovascular risk reduction: May provide additional endothelial benefits that support overall cardiovascular health in high‑risk patients.

Nebivolol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache reported. - Dizziness: transient dizziness, especially after standing. - Fatigue: feeling of tiredness or reduced energy. - Nasal congestion: mild nasal stuffiness. - Nausea: occasional mild gastrointestinal upset. - Insomnia: difficulty sleeping in some patients.

Serious or Rare Side Effects: - Bradycardia: excessively slow heart rate requiring medical attention. - Heart block: atrioventricular conduction disturbances. - Severe hypotension: marked drop in blood pressure causing faintness. - Allergic reactions: rash, pruritus, or angioedema that may need urgent care.

When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure patient safety. - Cardiovascular assessment: evaluate heart rate and rhythm before initiating therapy. - Renal impairment: adjust use in patients with severe kidney dysfunction. - Hepatic disease: use cautiously in moderate to severe liver impairment. - Concomitant β‑blockers: avoid combining with other β‑blockers to prevent excessive β‑blockade. - Pregnancy: category B; weigh potential benefits against unknown risks. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors: may increase nebivolol plasma levels, risking bradycardia. - Non‑selective β‑blockers: additive β‑blockade can cause severe hypotension. - Concomitant use with ivabradine: can cause excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Calcium channel blockers (verapamil, diltiazem): may enhance negative chronotropic effects. - Antihypertensive agents: combined use may require dose adjustments. - Antidiabetic drugs: β‑blockade can mask hypoglycaemia symptoms. - Antidepressants (SSRIs): may increase bradycardia risk.